NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis $236.58 -1.10 (-0.46%) (As of 09/20/2024 08:54 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Insulet Stock (NASDAQ:PODD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$231.23▼$237.9450-Day Range$180.69▼$237.6852-Week Range$125.82▼$243.98Volume1.35 million shsAverage Volume834,777 shsMarket Capitalization$16.59 billionP/E Ratio71.69Dividend YieldN/APrice Target$229.21Consensus RatingModerate Buy Company OverviewInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More… Forget Trump and Kamala (Ad)Forget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.Download my Dividend Calendar here Insulet Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 90th PercentileInsulet scored higher than 90% of companies evaluated by MarketBeat, and ranked 109th out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageInsulet has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insulet's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth26.32% Earnings GrowthEarnings for Insulet are expected to grow by 26.32% in the coming year, from $3.04 to $3.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 71.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 71.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 133.73.Price to Earnings Growth RatioInsulet has a PEG Ratio of 4.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 22.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insulet's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.16% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 3.18%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Sustainability and ESG4.9 / 5Environmental Score-1.20 Percentage of Shares Shorted4.16% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 3.18%, indicating that investor sentiment is decreasing. News and Social Media3.4 / 5News Sentiment1.07 News SentimentInsulet has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Insulet this week, compared to 9 articles on an average week.Search Interest9 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.47% of the stock of Insulet is held by insiders.Read more about Insulet's insider trading history. PODD Stock News HeadlinesInsulet (NASDAQ:PODD) PT Raised to $285.00 at Piper SandlerSeptember 19, 2024 | americanbankingnews.comPiper Sandler Sticks to Its Buy Rating for Insulet (PODD)September 17, 2024 | markets.businessinsider.comForget Trump and KamalaI hope you're deleting all those emails telling you how to make "1,000% gains" from the magic "Kamala Trade". It's nonsense. No one knows what's going to happen in November.September 23, 2024 | Investors Alley (Ad)Insider Sale: Director Timothy Scannell Sells 5,000 Shares of Insulet Corp (PODD)September 12, 2024 | finance.yahoo.comUpstart, Insulet And 2 Other Stocks Executives Are SellingSeptember 12, 2024 | benzinga.comInsulet’s Growth Trajectory Strengthened by Omnipod 5’s Expansion into Type 2 Diabetes MarketSeptember 11, 2024 | markets.businessinsider.comHere's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth TodaySeptember 11, 2024 | benzinga.comInsulet Corp (PODD) Trading 3.3% Higher on Sep 10September 10, 2024 | gurufocus.comSee More Headlines PODD Stock Analysis - Frequently Asked Questions How have PODD shares performed this year? Insulet's stock was trading at $216.98 at the beginning of 2024. Since then, PODD stock has increased by 9.0% and is now trading at $236.58. View the best growth stocks for 2024 here. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, August, 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts' consensus estimates of $0.56 by $0.01. The firm's revenue was up 23.2% compared to the same quarter last year. Who are Insulet's major shareholders? Insulet's top institutional investors include Baillie Gifford & Co. (2.69%), Clearbridge Investments LLC (1.91%), William Blair Investment Management LLC (1.35%) and American Century Companies Inc. (1.26%). Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, Wayde D Mcmillan, Bret Christensen, Mark N Field, Michael P Spears, Dan Manea, Prem Singh, Shacey Petrovic and Luciana Borio. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ) and Walt Disney (DIS). Company Calendar Last Earnings8/08/2024Today9/23/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$229.21 High Stock Price Target$285.00 Low Stock Price Target$184.00 Potential Upside/Downside-3.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$3.30 Trailing P/E Ratio71.69 Forward P/E Ratio77.82 P/E Growth4.38Net Income$206.30 million Net Margins21.11% Pretax Margin14.28% Return on Equity30.73% Return on Assets9.10% Debt Debt-to-Equity Ratio1.36 Current Ratio3.60 Quick Ratio2.71 Sales & Book Value Annual Sales$1.70 billion Price / Sales9.77 Cash Flow$3.84 per share Price / Cash Flow61.63 Book Value$10.49 per share Price / Book22.55Miscellaneous Outstanding Shares70,110,000Free Float69,711,000Market Cap$16.59 billion OptionableOptionable Beta1.21 Social Links This page (NASDAQ:PODD) was last updated on 9/23/2024 by MarketBeat.com Staff From Our PartnersThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | Sponsored[SHOCKING] Crypto Document Leak…A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Insulet Co. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.